TIDMKNB
Kanabo Group PLC
04 June 2021
4 June 2021
Kanabo Group Plc
("Kanabo" or "the Company")
Kanabo supports the "I am Billy" Campaign and Foundation to
promote wider NHS patient access to Medical Cannabis in UK
Kanabo Group Plc (LSE:KNB), a medical cannabis R&D Company
focused on the distribution of cannabis-derived products for
medical patients, and non-THC products for CBD consumers, is
delighted to announce its support for the "I am Billy" Campaign and
Foundation to promote wider NHS patient access to medical cannabis
in the UK.
Highlights
-- Kanabo named as designated innovation sponsor and partner of
the "I am Billy" campaign named after pioneering mother and son
Charlotte and Billy Caldwell
-- Andy Morrison, non-executive director of Kanabo, appointed as
trustee director of The I am Billy Foundation
-- "Walk with the Wizard" fund-raising campaign expected to
arrive in Westminster on 14 June 2021
The I am Billy Campaign ( https://www.iambilly.uk/our-campaign
)
I am Billy is a campaign brought forward by Billy and Charlotte
Caldwell, the mother and son who changed the UK medical cannabis
law in 2018. Billy Caldwell went on to pick up the first cannabis
medicine prescription funded by the NHS.
I am Billy is a pioneering medical cannabis campaign which seeks
to promote urgent and achievable solutions. Amongst these suggested
solutions is a proposal to carry out real world, evidence-based
studies at an I am Billy not-for-profit clinic. The studies will
combine data and academic research into the safety and efficacy of
cannabis-based medicines.
The campaign takes a positive and collaborative approach. It
presents potential solutions to 'unlock the deadlock' between
vulnerable and chronically ill patients and current prescription
practices in the UK and Channel Islands. It aims to address the
need for safe and consistent prescribing to ensure patients receive
the medicine they require via NHS funding and to provide
reassurance and confidence amongst NHS doctors to prescribe
cannabis medicines.
I am Billy is focused on the urgent needs and real experiences
of patients, but most importantly is focused on action to make a
real difference. The campaign focuses on the medicalisation and
legitimisation of cannabis as a medicine, along with the
innovations that are advancing the sector.
Kanabo is delighted to be named as the designated innovation
sponsor and partner of the I am Billy Campaign.
The I am Billy Foundation (
https://www.iambilly.uk/i-am-billy-foundation )
The foundation is a non-for-profit company that has as its
aims;
-- the relief of sickness through the provision of financial
assistance to those in need to meet the cost of cannabis based
medicinal products (CBMPs) prescribed by a named consultant on the
GMC specialist register and in accordance with clinical practice
recommendations; and
-- the advancement of education of the public in relation to the medicinal benefits of CBMPs,
Andy Morrison, non-executive director of Kanabo was appointed as
volunteer director and trustee of the I am Billy Foundation with
effect from 29 March 2021.
Walk with the Wizard (
https://www.iambilly.uk/walk-with-the-wizard )
On the 28 May 2021, Billy, Charlotte and some friends set off on
a 1000 mile walk from their home in Northern Ireland to Westminster
via the Channel Islands. The 'Walk with the Wizard' aims to raise
much-needed funds for the I am Billy Foundation to provide
financial assistance to vulnerable and chronically ill NHS patients
who cannot afford cannabis medicines.
The walk is expected to arrive in Westminster on or around 14
June 2021 and end at a round-table meeting with government
officials to present the I am Billy solutions.
By its support of the campaign, Kanabo aims to highlight
innovative products that exist on the market and which offer a
solution to concerns of the medical establishment. The Company
intends t o make medical cannabis formulations in the UK available
in combination with its unique medical device, the VapePod,
featuring consistent metred dosing. Kanabo intends to introduce the
first solution of inhaling cannabis in a safe and precise way,
replacing the common method of smoking medical cannabis
flowers.
Avihu Tamir, CEO of Kanabo commented : "We are delighted to
support Billy and Charlotte in their inspirational efforts to draw
attention to and resolve the difficulties experienced by patients
in accessing much-needed cannabis medicines. We believe that our
VapePod medical device which provides measured dosing of medicines
via inhalation will help give patients the instant relief they need
while giving doctors the confidence to prescribe."
Charlotte Caldwell, founder of the I am Billy Campaign and
Foundation added : "Billy and I are thrilled to have Kanabo as a
leading industry partner in the campaign and to benefit from Andy's
wealth of experience in the Foundation. Together, we aim to raise
awareness and bring relief to thousands of patients who could
benefit from medical cannabis."
For further information, please visit
http://www.kanabogroup.com/ or contact the following:
Kanabo Group Plc
Tel: +(972)52-3173-633
press@kanabogroup.com
Meirav Horn
Peterhouse Capital Limited (Financial Adviser)
Tel: +44 (0)20 7469 0930
Eran Zucker / Guy Miller / Allie Feuerlein
Peterhouse Capital Limited (Corporate Broker)
Lucy Williams / Charles Goodfellow
About Kanabo
Kanabo aims to be an industry leader in product development and
commercialisation of both cannabis-derived products for medical
patients and THC-free products for CBD consumers. The company
develops high-quality medical cannabis extract formulas, medical
device vaporisers, and other innovative delivery methods.
Validation activities are conducted at Kanabo's research lab at the
Weizmann Science Park in Israel. With a primary focus on the German
and UK Markets, Kanabo has already begun penetrating the European
Market, and is positioned to scale up to meet growing market demand
and projected sales. Currently, Kanabo is selling its line of CBD
formulas for inhalation in the UK and Germany and has agreements
with distributors in the pharmaceutical and OTC sectors already in
place.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFJMRTMTAMBMB
(END) Dow Jones Newswires
June 04, 2021 02:00 ET (06:00 GMT)
Spinnaker Opportunities (LSE:SOP)
Historical Stock Chart
From Apr 2024 to May 2024
Spinnaker Opportunities (LSE:SOP)
Historical Stock Chart
From May 2023 to May 2024